Uterine Fibroids (M12-817)

The purpose of this study is to determine the safety of elagolix and how elagolix works when compared to placebo in reducing heavy menstrual bleeding, the major symptom of uterine fibroids.

Register Today!

Trial Information

StatusIn Recruitment
Start DateNovember 2016
End Date2018
Trial Duration20 months
Number of Visits16-22
Lead CRCAdam Pawluch

For additional information
on this trial contact: